Abstract:Structural classification and regulatory functions of histone deacetylases and their inhibitors. Epigenetic regulation of genes through posttranslational regulation of proteins is a well‐explored approach for disease treatment, particularly in cancer chemotherapy. Histone deacetylases have shown significant potential as effective drug targets in therapeutic studies aiming to restore epigenetic normality in oncology. Besides their role in modifying histones, histone deacetylases can also catalyze the deacetylation of various nonhistone proteins and participate in the regulation of multiple biological processes. This paper provides a review of the classification, structure, and functional characteristics of the four classes of human histone deacetylases. The increasing abundance of structural information on HDACs has led to the gradual elucidation of structural differences among subgroups and subtypes. This has provided a reasonable explanation for the selectivity of certain HDAC inhibitors. Currently, the US FDA has approved a total of six HDAC inhibitors for marketing, primarily for the treatment of various hematological tumors and a few solid tumors. These inhibitors all have a common pharmacodynamic moiety consisting of three parts: CAP, ZBG, and Linker. In this paper, the structure–effect relationship of HDAC inhibitors is explored by classifying the six HDAC inhibitors into three main groups: isohydroxamic acids, benzamides, and cyclic peptides, based on the type of inhibitor ZBG. However, there are still many questions that need to be answered in this field. In this paper, the structure‐functional characteristics of HDACs and the structural information of the pharmacophore model and enzyme active region of HDAC is are considered, which can help to understand the inhibition mechanism of the compounds as well as the rational design of HDACs. This paper integrates the structural‐functional characteristics of HDACs as well as the pharmacophore model of HDAC is and the structural information of the enzymatic active region, which not only contributes to the understanding of the inhibition mechanism of the compounds, but also provides a basis for the rational design of HDAC inhibitors.

The Development Process: from SAHA to Hydroxamate HDAC Inhibitors with Branched CAP Region and Linear Linker

New Development of HDAC Inhibitors As Anti-Cancer Agents

Strategies in Developing Promising Histone Deacetylase Inhibitors.

Technologies of Targeting Histone Deacetylase in Drug Discovery: Current Progress and Emerging Prospects.

Selective histone deacetylase small molecule inhibitors: recent progress and perspectives

Histone Deacetylase (HDAC) Inhibitors in Cancer: a Patent Review (2017-Present)

Selective Histone Deacetylase Inhibitors with Anticancer Activity.

Development of N-Hydroxycinnamamide-Based Hdac Inhibitors with Improved Hdac Inhibitory Activity and in Vitro Antitumor Activity

Discovery and Development of HDAC Inhibitors: Approaches for the Treatment of Cancer a Mini-review

An Update On The Emerging Approaches For Histone Deacetylase (Hdac) Inhibitor Drug Discovery And Future Perspectives

Design, Synthesis, And Activity Of Hdac Inhibitors With A N-Formyl Hydroxylamine Head Group

Discussion on structure classification and regulation function of histone deacetylase and their inhibitor

Exploring the role of histone deacetylase inhibitors in cancer development and therapeutic potential

Targeting histone deacetylases for cancer therapy: Trends and challenges

Hydroxamic Acid Hybrids: Histone Deacetylase Inhibitors with Anticancer Therapeutic Potency

Research advances in the use of histone deacetylase inhibitors for epigenetic targeting of cancer.

Emerging therapeutic strategies in cancer therapy by HDAC inhibition as the chemotherapeutic potent and epigenetic regulator

Development of Novel Hydroxy Amide‐Based HDAC1 Inhibitors: Integrated Pharmacophore Modelling, 3D‐QSAR, and Virtual Screening Studies

Next-generation of Selective Histone Deacetylase Inhibitors

HDAC-targeting epigenetic modulators for cancer immunotherapy

An Overview of HDAC Inhibitors and Their Synthetic Routes.